Table 4.
Decisional conflict and knowledge at baseline and post-intervention.
| Score | Pre-n, yes (%) | Post-n, yes (%) | Difference | p-value | |
|---|---|---|---|---|---|
| Decisional conflict (N = 51) | |||||
| Sure of myself | 16 (31) | 23 (45) | – | – | |
| Understand information | 18 (35) | 43 (84) | – | – | |
| Risk-benefit ratio | 27 (53) | 39 (76) | – | – | |
| Encouragement | 25 (49) | 35 (69) | – | – | |
| Mean (SD) | 1.69 (1.35) | 2.69 (1.26) | 1.00 (1.57) | <0.001 | |
| Knowledge (N = 52) | n, correct (%) | n, correct (%) | |||
| What are relapses? | 51 (98) | 51 (98) | – | – | |
| When can a diagnosis of MS be made? | 50 (96) | 52 (100) | – | – | |
| What is the general effect of disease modifying therapies? | 34 (65) | 21 (40) | – | – | |
| Which DMTs are administered by self-injections? | 17 (33) | 28 (54) | – | – | |
| Compared to beta-interferons, what is the effect of Copaxone on relapse rates? | 8 (15) | 48 (92) | – | – | |
| If 100 patients start an interferon treatment, how many would have flu-like symptoms in the beginning? | 2 (4) | 51 (98) | – | – | |
| Which DMT(s) put you at an increased risk of developing PML? | 2 (4) | 25 (48) | – | – | |
| Mean (SD) | 3.15 (1.02) | 5.31 (1.42) | 2.15 (1.58) | <0.001 | |
MS: multiple sclerosis; DMT: disease modifying therapy; PML: progressive multifocal leukoencephalopathy.